ACMSD, a pivotal regulator of the kynurenine pathway, offers a novel therapeutic strategy to combat NAD+ depletion, a core metabolic defect in stroke driving mitochondrial dysfunction and cognitive decline. This evidence concerns the gene ACMSD and Stroke.